IP Library Granted Patent US 7,491,817
Granted Patent B2
US 7,491,817 · App. 10/851,289 · Granted Feb 17, 2009

Universal supports for oligonucleotide synthesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,491,817
App. No.
10/851,289
Granted
Feb 17, 2009
Kind
B2
Abstract

Universal supports for oligonucleotide synthesis include a support material represented by the following formula: In this formula, substituent A is selected from H, alkyl, aryl, or a polymeric or silica base material; substituent B is selected from acyl, aroyl, or a polymeric or silica base material; and substituent C is selected from a dimethoxytrityl group or a protecting group removable under acidic or neutral conditions. For the supports, one of substituents A or B constitutes the polymeric or silica base material. In use, an oligonucleotide is attached to the support at substituent C.

Claims (38)

1. A support for oligonucleotide synthesis comprising: a support material represented by the following formula:

wherein substituent A is a member selected from the group consisting of a polymeric base material and a silica base material;

wherein substituent B is a member selected from the group consisting of an acyl group and an aroyl group; and

wherein substituent C is a member selected from the group consisting of a dimethoxytrityl group and a protecting group removable under acidic or neutral conditions.

2. A support according to claim 1 , wherein substituent A constitutes a long chain alkylamino controlled pore glass base material.

3. A support according to claim 2 , wherein sub stituent A includes the following substituent:

wherein lcaaCPG and its accompanying substituent groups represent the long chain alkylamino controlled pore glass base material.

4. A support according to claim 2 , wherein substituent B is an acyl group.

5. A support according to claim 2 , wherein substituent B is a dichioroacetyl group.

6. A support according to claim 2 , wherein substituent B is a formyl group.

7. A support according to claim 2 , wherein substituent B is a chioroacetyl group.

8. A support according to claim 2 , wherein substituent B is a trichioroacetyl group.

9. A support according to claim 2 , wherein substituent B is a 4-chlorophenoxyacetyl group.

10. A support according to claim 2 , wherein substituent B is a 2,4-dichiorophenoxyacetyl group.

11. An article represented by the following formula:

wherein substituent A is a member selected from the group consisting of a polymeric base material, and a silica base material;

wherein substituent B is a member selected from the group consisting of an acyl group and an aroyl group; and

wherein substituent C is a member selected from the group consisting of a dimethoxytrityl group, a nucleotide-containing group, and a protecting group removable under acidic or neutral conditions.

12. An article according to claim 11 , wherein substituent A constitutes a long chain alkylamino controlled pore glass base material.

13. An article according to claim 12 , wherein substituent A includes the following substituent:

wherein lcaaCPG and its accompanying substituent groups represent the long chain alkylamino controlled pore glass base material.

14. An article according to claim 12 , wherein sub stituent A includes the following substituent:

wherein Oligoprep 250 and its accompanying substituent groups represent the PVA base material.

15. An article according to claim 12 , wherein substituent B is an acyl group.

16. An article according to claim 12 , wherein substituent B is a dichioroacetyl group.

17. An article according to claim 12 , wherein substituent B is a formyl group.

18. An article according to claim 12 , wherein substituent B is a chloroacetyl group.

19. An article according to claim 12 , wherein substituent B is a trichioroacetyl group.

20. An article according to claim 12 , wherein substituent B is a 4-chiorophenoxyacetyl group.

21. An article according to claim 12 , wherein substituent B is a 2,4-dichlorophenoxyacetyl group.

22. An article according to claim 11 , represented by the following formula:

wherein lcaaCPG and its accompanying substituent groups represent a long chain alkylamino controlled pore glass base material.

23. An article according to claim 11 , represented by the following formula:

wherein lcaaCPG and its accompanying substituent groups represent a long chain alkylamino controlled pore glass base material.

24. An article according to claim 11 , wherein substituent C is a nucleotide-containing group including at least one nucleotide selected from the group consisting of: thymidine, 2′-deoxyadenosine, 2′-deoxycytindine, and 2′-deoxyguanosine.

25. An article according to claim 24 , wherein the nucleotide-containing group is attached via a phosphotriester group.

26. An article according to claim 11 , wherein substituent C is a nucleotide-containing group including a plurality of nucleotides.

27. An article according to claim 11 , wherein substituent C is a nucleotide-containing group.

Assignments (8)
RELEASE OF FIRST LIEN SECURITY INTEREST Recorded Oct 19, 2020
From: JPMORGAN CHASE BANK, N.A.
To: VECTOR LABORATORIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH, LLC
Reel/Frame 054118/0751 →
RELEASE OF SECOND LIEN SECURITY INTEREST Recorded Oct 19, 2020
From: ANTARES CAPITAL LP
To: VECTOR LABORATORIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH, LLC
Reel/Frame 054118/0763 →
SECURITY AGREEMENT Recorded Oct 19, 2020
From: MARAVAI LIFE SCIENCES, INC.; TRILINK BIOTECHNOLOGIES, LLC; VECTOR LABORATORIES, INC.; GLEN RESEARCH, LLC; CYGNUS TECHNOLOGIES, LLC; MOCKV SOLUTIONS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 054118/0848 →
ENTITY CONVERSION Recorded Oct 16, 2020
From: GLEN RESEARCH CORPORATION
To: GLEN RESEARCH, LLC
Reel/Frame 054094/0001 →
RELEASE AND REASSIGNMENT OF SECURITY INTEREST RECORDED AT REEL/FRAME 44275/0032 Recorded Sep 13, 2018
From: NXT CAPITAL, LLC
To: GLEN RESEARCH, LLC
Reel/Frame 047073/0116 →
SECURITY AGREEMENT Recorded Aug 3, 2018
From: TRILINK BIOTECHNOLOGIES; TRILINK BIOTECHNOLOGIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH CORPORATION
To: ANTARES CAPITAL LP, AS COLLATERAL AGENT
Reel/Frame 046702/0651 →
SECURITY AGREEMENT Recorded Aug 2, 2018
From: TRILINK BIOTECHNOLOGIES; TRILINK BIOTECHNOLOGIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH CORPORATION
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 046708/0095 →
SECURITY INTEREST Recorded Dec 1, 2017
From: GLEN RESEARCH, LLC
To: NXT CAPITAL, LLC, AS AGENT
Reel/Frame 044275/0032 →